CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS)

Pediatric Nephrology

Volumn 31, Issue 1, 2016, Pages 157-161

  Caillaud, Caroline ^a   Zaloszyc, Ariane ^a   Licht, Christoph ^b   Pichault, Valérie ^c   Frémeaux Bacchi, Véronique ^d   Fischbach, Michel ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c CENTRE HOSPITALIER DE MULHOUSE   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

CFH gene mutation; Child; Complement; Eculizumab; Shigatoxin; Shigatoxin associated hemolytic uremic syndrome

Indexed keywords

AZITHROMYCIN; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; CREATININE; ECULIZUMAB; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE; UREA; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; C3 PROTEIN, HUMAN; COMPLEMENT FACTOR H, HUMAN; GENETIC MARKER; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ACUTE GASTROENTERITIS; ACUTE KIDNEY FAILURE; ARTICLE; CASE REPORT; CHILD; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIURESIS; ERYTHROCYTE TRANSFUSION; GENE MUTATION; GENETIC ANALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOTHERAPY; JAUNDICE; KIDNEY FUNCTION; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PALLOR; PRESCHOOL CHILD; PRIORITY JOURNAL; SHIGA TOXIN ASSOCIATED HEMOLYTIC UREMIC SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; VACCINATION; VOMITING; WEIGHT REDUCTION; ADOLESCENT; BLOOD; COMPLICATION; DNA MUTATIONAL ANALYSIS; ESCHERICHIA COLI INFECTIONS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HEMOLYTIC-UREMIC SYNDROME; HETEROZYGOTE; MICROBIOLOGY; MUTATION; PATHOGENICITY; PHENOTYPE; RISK FACTOR; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; COMPLEMENT C3; COMPLEMENT FACTOR H; DNA MUTATIONAL ANALYSIS; ESCHERICHIA COLI INFECTIONS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HEMOLYTIC-UREMIC SYNDROME; HETEROZYGOTE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MENINGOCOCCAL VACCINES; MUTATION; PHENOTYPE; RISK FACTORS; SHIGA-TOXIGENIC ESCHERICHIA COLI; TREATMENT OUTCOME;

EID: 84947485143     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-015-3207-2     Document Type: Article

References (31)

1. Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16:1035–1050
2. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676–1687
3. Waters AM, Licht C (2011) aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 26:41–57
4. Loirat C, Noris M, Fremeaux-Bacchi V (2008) Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 23:1957–1972
5. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554–562
6. Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H (2009) Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:1920–1924
7. Ferraris JR, Ferraris V, Acquier AB, Sorroche PB, Saez MS, Ginaca A, Mendez CF (2015) Activation of the alternative pathway of complement during the acute phase of typical hemolytic uremic syndrome. Clin Exp Immunol 181:118–125
8. Orth D, Wurzner R (2010) Complement in typical hemolytic uremic syndrome. Semin Thromb Hemost 36:620–624
9. Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Würzner R (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182:6394–6400
10. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114[2 Suppl 4th Report]:555–576
11. Trachtman H (2013) HUS and TTP in children. Pediatr Clin N Am 60:1513–1526
12. Borgatta B, Kmet-Lunacek N, Rello J (2012) E. coli O104:H4 outbreak and haemolytic-uraemic syndrome. Med Intensiva 36:576–583
13. Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Huguess A, Woods KM, Goodship JA, Goodship THJ (2006) Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 3:e431
14. Malina M, Roumenina LT, Seeman T, Le Quintrec M, Dragon-Durey MA, Schaefer F, Fremeaux-Bacchi V (2012) Genetics of hemolytic uremic syndromes. Presse Med 41:e105–114
15. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V (2011) Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 365:8–26
16. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschênes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392–2400
17. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschênes G, Coppo P, Herman Fridman W, Weiss L (2004) Heterozygous and homozygous Factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 15:787–795
18. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, Van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859
19. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham CC, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fougue D, Furman RR, Gaber O, Herthelius M, Houmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181
20. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx MJ, Le Deist F, Niaudet P, Schaefer F (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561–2563
21. Braune SA, Wichmann D, von Heinz MC, Nierhaus A, Becker H, Meyer TN, Meyer GP, Müller-Schulz M, Fricke J, De Weerth A, Hoepker WW, Fiehler J, Magnus T, Gerloff C, Panzer U, Stahl RAK, Wegsheider K, Kluge S (2013) Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med 41:1702–1710
22. Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C (2011) Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187:172–180
23. Locatelli M, Buelli S, Pezzotta A, Corna D, Perico L, Tomasoni S, Rottoli D, Rizzo P, Conti D, Thurman JM, Remuzzi G, Zoja C, Morigi M (2014) Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. J Am Soc Nephrol 25:1786–1798
24. Ehrlenbach S, Rosales A, Posch W, Wilflingseder D, Hermann M, Brockmeyer J, Karch H, Satchell SC, Würzner R, Orth-Höller D (2013) Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immun 81:2678–2685
25. Orth D, Ehrlenbach S, Brockmeyer J, Khan AB, Huber G, Karch H, Sarg B, Lindner H, Würzner R (2010) EspP, a serine protease of enterohemorrhagic Escherichia coli, impairs complement activation by cleaving complement factors C3/C3b and C5. Infect Immun 78:4294–4301
26. Arvidsson I, Stahl AL, Hedstrom MM, Kristoffersson AC, Rylander C, Westman JS, Storry JR, Olsson ML, Karpman D (2015) Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol 194:2309–2318
27. Stahl AL, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117:5503–5513
28. Poolpol K, Orth-Holler D, Speth C, Zipfel PF, Skerka C, de Cordoba SR, Brockmeyer J, Bielaszewska M, Würzner R (2014) Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 58:77–84
29. Paixao-Cavalcante DBM, Cook HT, Pickering MC (2008) Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice. Clin Exp Immunol 155:339–347
30. Noris M, Ruggenenti P, Perna A, Orisio S, Caprioli J, Skerka C, Vasile B, Zipfel PF, Remuzzi G (1999) Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 10:281–293
31. Alberti M, Valoti E, Piras R, Bresin E, Galbusera M, Tripodo C, Thaiss F, Remuzzi G, Noris M (2013) Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. Am J Transplant 13:2201–2206